Frazier Life Sciences invests globally in private and publicly-traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier Life Sciences manages over $3.9 billion in capital, including venture funds focusing on company creation and private companies, and a public fund focused on small and mid-cap public companies. Since 2005, over 60 Frazier Life Sciences portfolio companies, many of which were created or seeded by Frazier, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals with deep expertise in biopharmaceuticals, primarily located in Palo Alto, California (headquarters), San Diego, Seattle, Boston, New York, and London. For more information about Frazier Life Sciences, please visit www.frazierls.com.
Employees: 51-200
Portfolio 46
| Date | Name | Website | Total Raised | Location |
| - | Enlaza The... | enlazatx.com | $161M | United Sta... |
| - | Sudo Biosc... | sudobio.com | $300M | United Sta... |
| - | Krystal Bi... | krystalbio.com | - | United Sta... |
| - | Nabriva Th... | nabriva.com | $120M | Ireland, D... |
| - | Achaogen | zemdri.com | - | - |
| - | Cirius | ciriustx.com | $40M | United Sta... |
| - | Scout Bio | scoutbio.co | $20M | - |
| - | AnaptysBio | anaptysbio.com | $73.9M | United Sta... |
| - | Pardes Bio... | pardesbio.com | $250.61M | United Sta... |
| - | Alpha-9 Th... | alpha9tx.com | $75M | United Sta... |
Show more
Persons 64
| Date | First Name | Last Name | Title | Location | |||
| - | Kate | Schykeryne... | Investor R... | linkedin.c... | - | - | - |
| - | Lin | Mu, M.D., ... | Senior Ass... | linkedin.c... | - | - | - |
| - | Anna | H. Chen, P... | Principal | linkedin.c... | - | - | - |
| - | Ali | Jackson | Counsel – ... | linkedin.c... | - | - | - |
| - | Stacy | Clark | Office Man... | linkedin.c... | - | - | - |
| - | Cass | Childers | Senior Acc... | linkedin.c... | - | - | - |
| - | Chris | Peetz | Entreprene... | linkedin.c... | - | - | - |
| - | Sydnie | Heberling | Director o... | linkedin.c... | - | - | - |
| - | Maggie | Cheng | Executive ... | linkedin.c... | - | - | - |
| - | Don | Frail, Ph.... | Senior Adv... | linkedin.c... | - | - | - |
Show more
Mentions in press and media 3
| Date | Title | Description |
| 03.03.2025 | Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept | Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience Financing led by Frazier Life Sciences with signif... |
| 13.11.2024 | Alentis Therapeutics Secures $181.4 Million to Pioneer Cancer Treatments | In a bold move to reshape cancer treatment, Alentis Therapeutics has successfully raised $181.4 million in an oversubscribed Series D funding round. This infusion of capital, led by OrbiMed and co-led by Novo Holdings and Jeito Capital, sig... |
| 12.11.2024 | Alentis Therapeutics raises $181.4 million in oversubscribed series D round | Normal 0 false false false EN-GB X-NONE AR-SA Besides OrbiMed, Novo Holdings and Jeito Capital, Alentis Therapeutics’ series D round saw the participation of new investors Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Hea... |